MA34559B1 - Formulation pour le traitement du cancer - Google Patents

Formulation pour le traitement du cancer

Info

Publication number
MA34559B1
MA34559B1 MA32171A MA32171A MA34559B1 MA 34559 B1 MA34559 B1 MA 34559B1 MA 32171 A MA32171 A MA 32171A MA 32171 A MA32171 A MA 32171A MA 34559 B1 MA34559 B1 MA 34559B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
formulation
kits
methods
Prior art date
Application number
MA32171A
Other languages
English (en)
Inventor
Valeria Ossovskaya
Lingyun Li
Barry Sherman
Original Assignee
Bipar Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39350967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34559(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc
Publication of MA34559B1 publication Critical patent/MA34559B1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSITIONS, DES TROUSSES ET LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DU CANCER ET DE PATHOLOGIES VIRALES. PLUS PARTICULIÈREMENT, L'INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT DES COMPOSÉS DE NITROBENZAMIDE PRÉSENTANT UNE SOLUBILITÉ ACCRUE DANS DES SOLUTIONS AQUEUSES.
MA32171A 2007-01-16 2008-01-16 Formulation pour le traitement du cancer MA34559B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88075507P 2007-01-16 2007-01-16
PCT/US2008/051214 WO2008089272A1 (fr) 2007-01-16 2008-01-16 Préparations pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA34559B1 true MA34559B1 (fr) 2013-10-02

Family

ID=39350967

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32171A MA34559B1 (fr) 2007-01-16 2008-01-16 Formulation pour le traitement du cancer

Country Status (32)

Country Link
US (1) US20080176946A1 (fr)
EP (2) EP2121139B1 (fr)
JP (1) JP2010516626A (fr)
KR (1) KR20090113852A (fr)
CN (1) CN101668561A (fr)
AU (1) AU2008206294A1 (fr)
BR (1) BRPI0806590A2 (fr)
CA (1) CA2674600A1 (fr)
CO (1) CO6220840A2 (fr)
CR (1) CR10975A (fr)
CY (1) CY1113819T1 (fr)
DK (1) DK2121139T3 (fr)
DO (1) DOP2009000178A (fr)
EC (1) ECSP099577A (fr)
ES (1) ES2395690T3 (fr)
GB (1) GB2447796C (fr)
GT (1) GT200900201A (fr)
HR (1) HRP20120960T1 (fr)
IL (1) IL199682A0 (fr)
MA (1) MA34559B1 (fr)
MX (1) MX2009007596A (fr)
NZ (1) NZ579098A (fr)
PL (1) PL2121139T3 (fr)
PT (1) PT2121139E (fr)
RS (1) RS52633B (fr)
RU (2) RU2481830C2 (fr)
SG (1) SG178714A1 (fr)
SI (1) SI2121139T1 (fr)
SV (1) SV2009003335A (fr)
TN (1) TN2009000292A1 (fr)
UA (1) UA100852C2 (fr)
WO (1) WO2008089272A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
BRPI0611814A2 (pt) * 2005-06-10 2008-12-09 Bipar Sciences Inc moduladores parp e tratamento de cÂnceres
RU2447889C2 (ru) 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
CN101522609A (zh) 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
CA2662337A1 (fr) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthese d'acides gras au moyen d'inhibiteurs parp et methodes de traitement associees
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
EP2211854A4 (fr) * 2007-10-19 2011-01-12 Bipar Sciences Inc Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
US20090275608A1 (en) * 2008-02-04 2009-11-05 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (fr) * 2008-09-26 2010-04-01 George Nelson Méthode de traitement de la polyarthrite rhumatoïde, des tremblements/de la maladie de parkinson et de la sclérose en plaques
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
CA2833914A1 (fr) * 2011-05-10 2012-11-15 Universite Laval Procedes pour le traitement et le diagnostic de l'hypertension arterielle pulmonaire
MA38121A1 (fr) * 2012-11-30 2016-10-31 Glaxosmithkline Llc Nouvelle composition pharmaceutique
US10610590B2 (en) * 2016-05-02 2020-04-07 Symbios Technologies, Inc. Electrochemical plasma activated aqueous chemotherapeutics
WO2018237327A1 (fr) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
WO2019067991A1 (fr) * 2017-09-29 2019-04-04 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations
US12295938B2 (en) 2019-06-04 2025-05-13 Samsung Life Public Welfare Foundation Composition for treating castration-resistant prostate cancer, comprising quassinoids
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) * 2021-09-29 2024-01-03 Siemens Healthcare Gmbh Method of operating a magnetic resonance scanner
WO2023239919A1 (fr) * 2022-06-10 2023-12-14 Dana-Farber Cancer Institute, Inc. Un déséquilibre allélique de l'accessibilité de la chromatine dans le cancer identifie des variants de risque causal et leurs mécanismes

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0348655A (ja) * 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンｄ↓２類の安定化
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
WO1998045253A1 (fr) * 1997-04-10 1998-10-15 Isotechnika, Inc. Derives d'iode actives utilises dans le traitement du cancer et du sida
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
WO2002055076A1 (fr) * 2001-01-04 2002-07-18 Daiichi Pharmaceutical Co., Ltd. Preparation pharmaceutique contenant de la cyclodextrine
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
KR20050100616A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제
WO2005023765A1 (fr) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Methode de catalyse de reactions d'amidation au moyen de co2
BRPI0611814A2 (pt) * 2005-06-10 2008-12-09 Bipar Sciences Inc moduladores parp e tratamento de cÂnceres
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
CN101522609A (zh) * 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
CA2662337A1 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthese d'acides gras au moyen d'inhibiteurs parp et methodes de traitement associees

Also Published As

Publication number Publication date
MX2009007596A (es) 2009-08-13
SI2121139T1 (sl) 2013-01-31
HK1137158A1 (en) 2010-07-23
ECSP099577A (es) 2009-10-30
CN101668561A (zh) 2010-03-10
CO6220840A2 (es) 2010-11-19
RU2009130599A (ru) 2011-02-27
CR10975A (es) 2009-10-15
GB2447796B (en) 2009-03-04
CY1113819T1 (el) 2016-07-27
HK1121697A1 (zh) 2009-04-30
EP2121139B1 (fr) 2012-10-10
SV2009003335A (es) 2010-02-05
RU2012151571A (ru) 2014-06-10
RU2481830C2 (ru) 2013-05-20
WO2008089272A1 (fr) 2008-07-24
EP2121139A1 (fr) 2009-11-25
NZ579098A (en) 2012-07-27
IL199682A0 (en) 2010-04-15
KR20090113852A (ko) 2009-11-02
CA2674600A1 (fr) 2008-07-24
AU2008206294A1 (en) 2008-07-24
GB2447796C (en) 2009-11-12
JP2010516626A (ja) 2010-05-20
EP2476461A3 (fr) 2012-10-24
GB0807263D0 (en) 2008-05-28
BRPI0806590A2 (pt) 2013-07-23
SG178714A1 (en) 2012-03-29
PT2121139E (pt) 2012-12-12
GB2447796A (en) 2008-09-24
ES2395690T3 (es) 2013-02-14
TN2009000292A1 (en) 2010-12-31
EP2476461A2 (fr) 2012-07-18
US20080176946A1 (en) 2008-07-24
PL2121139T3 (pl) 2013-03-29
GT200900201A (es) 2011-06-23
DK2121139T3 (da) 2013-01-14
HRP20120960T1 (hr) 2012-12-31
UA100852C2 (ru) 2013-02-11
RS52633B (sr) 2013-06-28
DOP2009000178A (es) 2009-10-31

Similar Documents

Publication Publication Date Title
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TN2010000154A1 (fr) Composition destinee a la regulation du metabolism des lipides
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
EA200900351A1 (ru) Ингибиторы тирозинкиназы брутона
MA44851B1 (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
TN2009000292A1 (en) Formulations for cancer treatment
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
MA31183B1 (fr) Inhibiteurs de mek
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA32014B1 (fr) Composes condenses de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA29243B1 (fr) Agonistes de pyy et leurs utilisations
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués